Application of Pharmacogenomics and Bioinformatics to Exemplify the Utility of Human ex vivo Organoculture Models in the Field of Precision Medicine

It is well recognised that one size does not fit all when it comes to the treatment of many diseases. Getting the right drug to the right patient at the right dose has become the focus of precision medicine, which provides hope that patients may receive the most appropriate treatment sooner, improving their quality of life and reducing the support required from health care systems and wider society[1]. Health economists are recognising the potential of precision medicine and are beginning to apply the concept to their research[2].

Continue reading 

Will The Microbiome Become The Next Hot Topic For Cancer Research?

From obesity and Crohn’s disease to cancer, investigations into the microbiota and microbiome are opening up numerous avenues of research. The human microbiota, composed of microorganisms such as bacteria, viruses, eukaryotic microbes and many different species which occupy the human body[1], and the study of the associated microbial genomes, are generating increasing numbers of publications.

Continue reading 

TISSUE SPOTLIGHT: Lung

This issue, we are casting the REPROCELL Tissue Spotlight on the LUNG.

The lungs are the central organs of the human respiratory system enabling you to take around 25,000 breaths a day — mostly, without any conscious thought that you are doing so!

Continue reading 

Stem Cells for Autism

In this post, we highlight recent advancements in stem cells as treatment and study of autism to commemorate World Autism Awareness Day (2 April 2019).

Autism spectrum disorder (ASD) is a complex developmental disability that impairs the ability to communicate and relate to others. Affecting 1% of the world population, it is the most commonly diagnosed childhood developmental disorder. In 2018, Centers for Disease Control (CDC) reported that rates of autism had increased to an estimated 1 in 59 children, up from 1 in 88 just six years ago.

Continue reading 

Improving patient outcomes through collaboration

The return on R&D investments in the UK is at its lowest rate in nine years, despite Britain’s global presence in science, technology and health. Pharmaceutical attrition rates continue to rise, and the UK biotech landscape remains fragmented. Medicines Discovery Catapult (MDC) aims to connect the UK R&D community more effectively by putting the patient at the heart of the drug discovery process. As part of our collaboration with the MDC, REPROCELL have pledged to provide custom drug discovery assays using live human tissues.

Continue reading 

Spotlight: StemRNA Neuro iPSCs – Human Brain Neurons for Functional Assays

Human induced pluripotent stem cell (iPSCs) derived  neural models to study brain disease provide an unlimited resource for disease modelling as well as being a tool for drug screening for effective therapies. The limited access to viable patient neurons from brain tissue itself generates the need for functional and reproducible human neuron cell models. Such cells are now increasingly used for drug development studies as well as supporting research into mechanisms and pathways of various neurological diseases.

Continue reading 

3D epithelial barrier assays in vitro: How to get the best balance between practicability and physiological relevance

Barrier assays are an important tool for in vitro drug development and drug safety testing, e.g. assessing the absorption of a drug candidate through the intestinal wall or the corrosion of chemical compounds on skin.

Continue reading 

Using human iPSCs as an in vitro model for regenerative medicine, drug screening and disease modelling

In translational medicine, research using primary patient samples is advantageous over cell lines as the expression of the protein under investigation is regulated by native elements in primary samples.

Continue reading 

The gut microbiome in health and disease: the future for diagnosis and treatment of IBD and IBS?

A new method for distinguishing between IBD (inflammatory bowel disease) and IBS (irritable bowel syndrome) could be on the horizon following a publication by researchers from teams in the Netherlands and the US, who profiled the gut microbiome in stool samples from those with IBD, IBS and healthy controls.

Continue reading 

Tissue Sourcing for the Development of iPSC-derived Disease Models

Human induced pluripotent stem cells (iPSCs)-based models are an ideal resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by drug treatment[3]. Such iPSC-based models enable studies to be performed under defined experimental conditions and in a reproducible manner.

Continue reading